计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
CHIR-98014是一种有效的GSK-3α和GSK-3β抑制剂,IC50值分别为0.65 nM 和0.58 nM。 GSK-3(糖原合酶激酶3)是一种丝氨酸/苏氨酸蛋白激酶,在许多细胞内信号通路中具有关键作用,包括细胞增殖、迁移、炎症和免疫反应、葡萄糖调节和细胞凋亡。据报道,GSK-3在多种疾病中异常表达,包括II型糖尿病、阿尔茨海默病、炎症、癌症和躁郁症。 CHIR-98014是一种有效的GSK-3α和GSK-3β抑制剂。在表达胰岛素受体的CHO-IR细胞或原代大鼠肝细胞中,CHIR-98014以剂量依赖的方式刺激GS活性比,比基础水平高2-3倍。同样地,在胰岛素敏感的lean Zucker 大鼠和胰岛素抗性的ZDF大鼠来源的I型骨骼肌中,CHIR-98014激活GS活性比[1]。在小鼠ES-D3细胞中,CHIR-98014处理48和72小时后通过抑制GSK-3,从而显著激活Wnt/beta-catenin信号通路。 在明显糖尿病和胰岛素抗性db/db小鼠模型中,CHIR-98014(30 mg/kg)口服给药后4小时内显著减少空腹高血糖,在口服或静脉注射葡萄糖时改善了葡萄糖处理。
产品应用:
CHIR-98014 (CT98014)是一种有效的GSK-3α/β抑制剂,无细胞试验中IC50为0.65 nM/0.58 nM,作用于GSK-3比作用于其最密切的同源物Cdc2 和 ERK2选择性高。
Information
CHIR-98014 (CT98014) is a potentGSK-3α/βinhibitor withIC50of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
In vitro
CHIR-98014 inhibits human GSK-3β with Ki of 0.87 nM. CHIR-98014 is very effective in preventing murine and rat GSK-3. Although CHIR-98014 acts as a simple competitive inhibitor of ATP binding, it displays from 500-fold to >1000-fold selectivity for GSK-3 versus 20 other protein kinases including Cdc2, ERK2, Tie-2 and KDR. CHIR-98014 prevents Cdc2 with IC50 of 3.7 μM. However, CHIR 98014 reveals similar ptoency against the highly homologous ɑ and β isoforms of GSK-3, it is noteworthy that it stronly discriminated between GSK-3 and its closest homologs CDC2 and ERK2. Exposure of insulin receptor-expressing CHO-IR cells or primary rat hepatocytes to increasing concentrations of inhibitor CHIR98014 results in a two- to three-fold stimulation of the GS activity ratio above basal. The concentrations of CHIR-98014 giving rise to half-maximal GS stimulation (EC50) is 106 nM and 107 nM for CHO-IR and rat hepatocytes, respectively.
In vivo
GSK-3 inhibitor CHIR-98014 activates the GS activity ratio in isolated type I skeletal muscle from insulin-sensitive lean Zucker and from insulin-ressitant ZDF rats. Soleus muscle isolated from ZDF rats shows significant resistance to insulin for activation of GS but responded to 500 nM CHIR-98014 to the same extent (40% increase) as muscle from lean Zucker rats. Notably, GS activation by insulin plus CHIR-98014 is additive in muscle from lean Zucker rats and greater than additive in muscle from the ZDF rats. Total GS activity is not altered by either CHIR-98014 or insulin in these cells and muscles. Meanwhile, CHIR-98014 does not influence the insulin dose-response in muscle from lean animals. The reduction in hyperglycemia and improved glucose disposal are not limited to db/db mice and ZDF rats, as similar results are observed with ob/ob mice, diet-induced diabetic C57BL/6 mice, and glucose-intolerant SHHF rats treated with CHIR-98014. Additionally, CHIR-98014 decreases the phosphorylation (Ser396) of tau protein in the cortex and hippocampus of postnatal rats.
Cell Data
cell lines:
Concentrations:0.01-10 μM
Incubation Time:30 min
Powder Purity:≥99%